Combination of reovirus (pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGlio phase Ib trial
Authors
Short, S. C.Kendall, J.
Chalmers, A.
McBain, Catherine A
Melcher, A.
Samson, A.
Phillip, R.
Brown, S.
Affiliation
University of Leeds, Leeds, United Kingdom;Issue Date
2022
Metadata
Show full item recordCitation
Short SC, Kendall J, Chalmers A, McBain C, Melcher A, Samson A, et al. Combination of reovirus (pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGlio phase Ib trial. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509500043.Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2022-CT569Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2022-CT569Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2022-CT569